Dapagliflozin in Patients with Chronic Kidney Disease

Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann J, Mcmurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC (2020)

Publication Type: Journal article

Publication year: 2020

Journal

New England Journal of Medicine Massachusetts Medical Society

Book Volume: 383

Pages Range: 1436-1446

Journal Issue: 15

DOI: 10.1056/NEJMoa2024816

Abstract

BACKGROUND

Involved external institutions

University of Glasgow

United Kingdom (GB) Steno Diabetes Center

Denmark (DK) AstraZeneca UK Limited

United Kingdom (GB) Stanford University

United States (USA) (US) University of Sydney (USYD)

Australia (AU) University of Utah

United States (USA) (US) Southern Medical University / 南方医科大学

China (CN) Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Mexico (MX) University of Groningen / Rijksuniversiteit Groningen

Netherlands (NL) University of Texas Southwestern Medical Center (UT Southwestern)

United States (USA) (US)

How to cite

APA:

Heerspink, H.J.L., Stefansson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., Hou, F.-F.,... Wheeler, D.C. (2020). Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 383(15), 1436-1446. https://doi.org/10.1056/NEJMoa2024816

MLA:

Heerspink, Hiddo J. L., et al. "Dapagliflozin in Patients with Chronic Kidney Disease." New England Journal of Medicine 383.15 (2020): 1436-1446.

BibTeX: Download